Roger Pomerantz Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Roger Pomerantz.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Roger Pomerantz. Roger Pomerantz is Director in Viracta Therapeutics, Inc. ($SNSS) and Chief Executive Officer in CONTRAFECT Corp ($CFRX) and Director in CONTRAFECT Corp ($CFRX) and Director in Seres Therapeutics, Inc. ($MCRB) and President and CEO in Seres Therapeutics, Inc. ($MCRB) and Director in Intec Pharma Ltd. ($NTEC) and Director in Rubius Therapeutics, Inc. ($RUBY).
Latest Insider Trading Transactions of Roger Pomerantz
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CFRX, NTEC, RUBY, MCRB, SNSS
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 2021 | CFRX | CONTRAFECT Corp | Pomerantz Roger | Chief Executive Off ... | Option Exercise | A | 4.31 | 254,000 | 1,094,740 | 254,000 | |
| Mar 30 2021 | SNSS | Viracta Therapeuti ... | Pomerantz Roger | Director | Option Exercise | A | 8.74 | 135,000 | 1,179,900 | 135,000 | |
| Jul 17 2020 | NTEC | Intec Pharma Ltd. | Pomerantz Roger | Director | Option Exercise | A | 0.31 | 40,000 | 12,300 | 40,000 | |
| Jul 02 2019 | NTEC | Intec Pharma Ltd. | Pomerantz Roger | Director | Option Exercise | A | 4.86 | 20,000 | 97,160 | 20,000 | |
| Jul 02 2019 | NTEC | Intec Pharma Ltd. | Pomerantz Roger | Director | Option Exercise | A | 4.86 | 20,000 | 97,160 | 20,000 | |
| Jun 14 2019 | MCRB | Seres Therapeutics ... | Pomerantz Roger | Director | Option Exercise | A | 2.83 | 15,000 | 42,450 | 15,000 | |
| Sep 11 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.00 | 1,810 | 16,291 | 213,976 | 215.8 K to 214 K (-0.84 %) |
| Sep 06 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.04 | 3,013 | 27,235 | 215,786 | 218.8 K to 215.8 K (-1.38 %) |
| Sep 06 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.12 | 9,505 | 86,714 | 218,799 | 228.3 K to 218.8 K (-4.16 %) |
| Jul 23 2018 | RUBY | Rubius Therapeutic ... | Pomerantz Roger | Director | Buy | P | 23.00 | 100 | 2,300 | 100 | 0 to 100 |
| Jul 18 2018 | RUBY | Rubius Therapeutic ... | Pomerantz Roger | Director | Option Exercise | A | 23.00 | 25,000 | 575,000 | 25,000 | |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 1,010 | 717 | 797,536 | |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.01 | 1,010 | 9,099 | 228,304 | 229.3 K to 228.3 K (-0.44 %) |
| Jul 12 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 1,010 | 717 | 229,314 | 228.3 K to 229.3 K (+0.44 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 5,989 | 4,252 | 798,546 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 10,981 | 7,797 | 804,535 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 15,366 | 10,910 | 815,516 | |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.05 | 5,989 | 54,208 | 228,304 | 234.3 K to 228.3 K (-2.56 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 5,989 | 4,252 | 234,293 | 228.3 K to 234.3 K (+2.62 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.14 | 10,981 | 100,351 | 228,304 | 239.3 K to 228.3 K (-4.59 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 10,981 | 7,797 | 239,285 | 228.3 K to 239.3 K (+4.81 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.14 | 15,366 | 140,507 | 228,304 | 243.7 K to 228.3 K (-6.31 %) |
| Jul 10 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 15,366 | 10,910 | 243,670 | 228.3 K to 243.7 K (+6.73 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 4,496 | 3,192 | 830,882 | |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,560 | 15,308 | 835,378 | |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.10 | 4,496 | 40,915 | 228,304 | 232.8 K to 228.3 K (-1.93 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 4,496 | 3,192 | 232,800 | 228.3 K to 232.8 K (+1.97 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.15 | 21,560 | 197,375 | 228,304 | 249.9 K to 228.3 K (-8.63 %) |
| Jun 29 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,560 | 15,308 | 249,864 | 228.3 K to 249.9 K (+9.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,991 | 12,064 | 856,938 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,991 | 12,064 | 856,938 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,224 | 15,069 | 873,929 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 21,224 | 15,069 | 873,929 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,288 | 11,564 | 895,153 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 16,288 | 11,564 | 895,153 | |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.03 | 16,991 | 153,408 | 228,304 | 245.3 K to 228.3 K (-6.93 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.03 | 16,991 | 153,408 | 228,304 | 245.3 K to 228.3 K (-6.93 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,991 | 12,064 | 245,295 | 228.3 K to 245.3 K (+7.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,991 | 12,064 | 245,295 | 228.3 K to 245.3 K (+7.44 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.19 | 21,224 | 195,133 | 228,304 | 249.5 K to 228.3 K (-8.51 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.19 | 21,224 | 195,133 | 228,304 | 249.5 K to 228.3 K (-8.51 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,224 | 15,069 | 249,528 | 228.3 K to 249.5 K (+9.30 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,224 | 15,069 | 249,528 | 228.3 K to 249.5 K (+9.30 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.21 | 26,752 | 246,504 | 228,304 | 255.1 K to 228.3 K (-10.49 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.21 | 26,752 | 246,504 | 228,304 | 255.1 K to 228.3 K (-10.49 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,288 | 11,564 | 255,056 | 238.8 K to 255.1 K (+6.82 %) |
| Jun 27 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 16,288 | 11,564 | 255,056 | 238.8 K to 255.1 K (+6.82 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.36 | 40,057 | 374,761 | 238,768 | 278.8 K to 238.8 K (-14.37 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.06 | 18,987 | 172,094 | 278,825 | 297.8 K to 278.8 K (-6.38 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.33 | 26,492 | 247,051 | 297,812 | 324.3 K to 297.8 K (-8.17 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.36 | 40,057 | 374,761 | 238,768 | 278.8 K to 238.8 K (-14.37 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.06 | 18,987 | 172,094 | 278,825 | 297.8 K to 278.8 K (-6.38 %) |
| Jun 22 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 9.33 | 26,492 | 247,051 | 297,812 | 324.3 K to 297.8 K (-8.17 %) |
| Jan 30 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | A | 10.42 | 278,000 | 2,896,760 | 278,000 | |
| Jan 25 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 40,241 | 28,571 | 911,441 | |
| Jan 25 2018 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 40,241 | 28,571 | 324,537 | 284.3 K to 324.5 K (+14.15 %) |
| Jul 26 2017 | CFRX | CONTRAFECT Corp | Pomerantz Roger | Director | Option Exercise | P | 1.55 | 400 | 620 | 400 | |
| Jul 26 2017 | CFRX | CONTRAFECT Corp | Pomerantz Roger | Director | Buy | P | 1.24 | 800 | 992 | 800 | 0 to 800 |
| Jul 20 2017 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 100,604 | 71,429 | 951,682 | |
| Jul 20 2017 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 100,604 | 71,429 | 284,296 | 183.7 K to 284.3 K (+54.77 %) |
| Jan 27 2017 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | A | 9.89 | 261,000 | 2,581,290 | 261,000 | |
| Jul 28 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 20,000 | 14,200 | 1,052,286 | |
| Jul 28 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 35.00 | 20,000 | 700,000 | 183,692 | 203.7 K to 183.7 K (-9.82 %) |
| Jul 28 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 20,000 | 14,200 | 203,692 | 183.7 K to 203.7 K (+10.89 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 35,435 | 25,159 | 1,072,283 | |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 52,776 | 37,471 | 1,107,718 | |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.80 | 25,535 | 760,943 | 183,692 | 209.2 K to 183.7 K (-12.20 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.27 | 9,900 | 289,773 | 209,227 | 219.1 K to 209.2 K (-4.52 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 35,435 | 25,159 | 219,127 | 183.7 K to 219.1 K (+19.29 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.96 | 2,905 | 87,034 | 183,692 | 186.6 K to 183.7 K (-1.56 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.27 | 49,871 | 1,459,724 | 186,597 | 236.5 K to 186.6 K (-21.09 %) |
| Jul 07 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 52,776 | 37,471 | 236,468 | 183.7 K to 236.5 K (+28.73 %) |
| Jul 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 56,789 | 40,320 | 1,160,497 | |
| Jul 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.00 | 10,000 | 300,000 | 183,692 | 193.7 K to 183.7 K (-5.16 %) |
| Jul 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.84 | 41,957 | 1,251,997 | 193,692 | 235.6 K to 193.7 K (-17.80 %) |
| Jul 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.12 | 4,832 | 140,708 | 235,649 | 240.5 K to 235.6 K (-2.01 %) |
| Jul 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 56,789 | 40,320 | 240,481 | 183.7 K to 240.5 K (+30.92 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 74,049 | 52,575 | 1,217,286 | |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 33.22 | 20,307 | 674,639 | 183,692 | 204 K to 183.7 K (-9.95 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 32.34 | 47,159 | 1,525,122 | 203,999 | 251.2 K to 204 K (-18.78 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 31.62 | 6,583 | 208,154 | 251,158 | 257.7 K to 251.2 K (-2.55 %) |
| Jun 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 74,049 | 52,575 | 257,741 | 183.7 K to 257.7 K (+40.31 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 70,951 | 50,375 | 1,291,335 | |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.65 | 52,441 | 1,607,317 | 183,692 | 236.1 K to 183.7 K (-22.21 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.12 | 18,510 | 557,521 | 236,133 | 254.6 K to 236.1 K (-7.27 %) |
| Jun 02 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 70,951 | 50,375 | 254,643 | 183.7 K to 254.6 K (+38.62 %) |
| May 25 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 9,801 | 6,959 | 1,362,286 | |
| May 25 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.00 | 9,801 | 294,030 | 183,692 | 193.5 K to 183.7 K (-5.07 %) |
| May 25 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 9,801 | 6,959 | 193,493 | 183.7 K to 193.5 K (+5.34 %) |
| May 19 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 160,965 | 114,285 | 1,372,087 | |
| May 19 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 160,965 | 114,285 | 183,692 | 22.7 K to 183.7 K (+708.25 %) |
| May 09 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 8,507 | 6,040 | 1,533,052 | |
| May 09 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 25.10 | 308 | 7,731 | 22,727 | 23 K to 22.7 K (-1.34 %) |
| May 09 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 24.28 | 8,199 | 199,072 | 23,035 | 31.2 K to 23 K (-26.25 %) |
| May 09 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 8,507 | 6,040 | 31,234 | 22.7 K to 31.2 K (+37.43 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 30,027 | 21,319 | 1,541,559 | |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 29,298 | 20,802 | 1,571,586 | |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 26.34 | 8,900 | 234,426 | 22,727 | 31.6 K to 22.7 K (-28.14 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 8,900 | 6,319 | 31,627 | 22.7 K to 31.6 K (+39.16 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 25.48 | 21,127 | 538,316 | 22,727 | 43.9 K to 22.7 K (-48.18 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 21,127 | 15,000 | 43,854 | 22.7 K to 43.9 K (+92.96 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 27.31 | 700 | 19,117 | 22,727 | 23.4 K to 22.7 K (-2.99 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 700 | 497 | 23,427 | 22.7 K to 23.4 K (+3.08 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 26.52 | 28,598 | 758,419 | 22,727 | 51.3 K to 22.7 K (-55.72 %) |
| May 06 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 28,598 | 20,305 | 51,325 | 22.7 K to 51.3 K (+125.83 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 23,680 | 16,813 | 1,600,884 | |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 43,687 | 31,018 | 1,624,564 | |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.32 | 200 | 5,864 | 22,727 | 22.9 K to 22.7 K (-0.87 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 28.44 | 7,142 | 203,118 | 22,927 | 30.1 K to 22.9 K (-23.75 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 27.80 | 16,338 | 454,196 | 30,069 | 46.4 K to 30.1 K (-35.21 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 23,680 | 16,813 | 46,407 | 22.7 K to 46.4 K (+104.19 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.59 | 8,249 | 244,088 | 22,727 | 31 K to 22.7 K (-26.63 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 28.95 | 35,438 | 1,025,930 | 30,976 | 66.4 K to 31 K (-53.36 %) |
| May 04 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 43,687 | 31,018 | 66,414 | 22.7 K to 66.4 K (+192.23 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.48 | 44,825 | 21,516 | 84,212 | |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.48 | 90,963 | 43,662 | 129,037 | |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.00 | 788 | 23,640 | 22,727 | 23.5 K to 22.7 K (-3.35 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.68 | 6,416 | 190,427 | 23,515 | 29.9 K to 23.5 K (-21.44 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 29.18 | 22,418 | 654,157 | 29,931 | 52.3 K to 29.9 K (-42.82 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 28.17 | 15,203 | 428,269 | 52,349 | 67.6 K to 52.3 K (-22.51 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.48 | 44,825 | 21,516 | 67,552 | 22.7 K to 67.6 K (+197.23 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 27.56 | 12,377 | 341,110 | 22,727 | 35.1 K to 22.7 K (-35.26 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 26.67 | 38,080 | 1,015,594 | 35,104 | 73.2 K to 35.1 K (-52.03 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 25.69 | 40,506 | 1,040,599 | 73,184 | 113.7 K to 73.2 K (-35.63 %) |
| Apr 05 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.48 | 90,963 | 43,662 | 113,690 | 22.7 K to 113.7 K (+400.24 %) |
| Feb 03 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | A | 26.20 | 176,500 | 4,624,300 | 176,500 | |
| Apr 11 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.71 | 7,500 | 5,325 | 1,668,251 | |
| Apr 11 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | M | 0.48 | 1,712 | 822 | 82,500 | |
| Apr 11 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Sell | S | 30.00 | 9,212 | 276,360 | 22,727 | 31.9 K to 22.7 K (-28.84 %) |
| Apr 11 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.71 | 7,500 | 5,325 | 31,939 | 24.4 K to 31.9 K (+30.69 %) |
| Apr 11 2016 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | M | 0.48 | 1,712 | 822 | 24,439 | 22.7 K to 24.4 K (+7.53 %) |
| Jun 29 2015 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Option Exercise | C | 0.00 | 22,727 | 0 | 0 | |
| Jun 29 2015 | MCRB | Seres Therapeutics ... | Pomerantz Roger | President and CEO | Buy | C | 0.00 | 22,727 | 0 | 22,727 | 0 to 22.7 K |
Page: 1